Latest Clinical News

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (05-2-2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (04-28-2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA (04-27-2016)

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (04-25-2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Aplidin® Improves Progression-Free Survival in Multiple Myeloma (04-21-2016)

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following... Continue Reading

Fertility Rates Encouraging for Childhood Cancer Survivors (04-11-2016)

Fertility rates, including pregnancy and livebirth rates, for both male and female childhood cancer survivors were recently analyzed in a large study, indicating promising data in this emotionally charged issue among young cancer survivors. The results... Continue Reading

Financial Distress Associated with Mortality in Cancer Patients (04-7-2016)

Severe financial distress that requires filing for bankruptcy after a cancer diagnosis appears to increase mortality among cancer patients. These results were recently published in the Journal of Clinical Oncology. Treatment for cancer can be associated... Continue Reading

3D Mammography Proves More Accurate in Breast Cancer Detection (03-31-2016)

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (03-30-2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic... Continue Reading

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (03-29-2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (03-28-2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

Complete Pathologic Responses Associated with Prognosis in Triple-Negative Breast Cancer (03-24-2016)

A complete pathologic response (no cancer cells detected through microscopic evaluation) appears to be the most accurate indicator of long-term prognosis for women with triple-negative breast cancer. These results were recently presented at the 2015 annual... Continue Reading

Next Page »